Nanofilm Technologies (MZH) Q4 2021 TU earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2021 TU earnings summary
21 Oct, 2026Executive summary
4Q2021 update highlighted capacity-building investments, a rebound in 3C production, growth across other advanced materials segments, and progress in nanofabrication and hydrogen initiatives.
Inaugural sustainability report set 2030 targets across innovation, environment, social and governance, measured against a 2020 baseline.
Outlook and guidance
3C production momentum was expected to continue into 1Q2022; MLA production was ramping on schedule and expected to contribute positively to NFBU in 4Q2021 and beyond, barring unforeseen events.
2022 plans included accelerated development of core technologies and new products, with commercialization pathways advancing in sustainable materials, engineered optics and hydrogen fuel cells.
IEBU entered FY2022 with robust external-customer demand and a visible order book; Sydrogen was building production and R&D capacity in Shanghai and Singapore.
Segment performance
AMBU’s 3C production output rebounded as its peak period began in 4Q2021; Automotive, Precision Engineering, and Printing & Imaging continued strong growth from wider adoption of greener functional materials.
NFBU began mass production of its first micro-lens array project for next-generation wearables, with production ramping progressively according to schedule.
IEBU saw robust demand as customers resumed capital expenditure to expand production capacity; the order book was visible into FY2022.
Sydrogen focused on building production infrastructure and R&D capabilities for hydrogen fuel-cell technologies and core components.
Latest events from Nanofilm Technologies
- Record FY2021 results and expanded capacity set the stage for FY2022 growth.MZH
H2 2021 - Revenue grew 24.2%, while startup and NPI costs pressured profit and margins.MZH
H1 2021 - 2H recovery lifted earnings and margins, underpinning conditional FY2024 growth expectations.MZH
H2 2023 - Headwinds cut FY2022 results, while expansion and the 2025 targets remained on track.MZH
H2 2022 - Revenue fell 34.4% as consumer weakness drove a H1 loss; 2H revenue is expected higher.MZH
H1 2023 - FY2025 revenue rose 20% and PAT 58%, led by AMBU growth and an IEBU recovery.MZH
H2 2025 - Revenue rose 29.6% as PATMI returned to profit and adjusted EBITDA grew 46.1%.MZH
H1 2025 - Revenue grew 13%, adjusted EBITDA rose 61.4%, and FY2024 growth is expected.MZH
H1 2024 - Revenue rose 15% and adjusted EBITDA 31%, supported by growth and global expansion.MZH
H2 2024